問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Thoracic Medicine

Taipei Tzu Chi Hospital

Division of General Surgery

Taipei Medical University Hospital

Division of Dermatology

更新時間:2023-09-19

楊雅雯
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

16Cases

2021-06-01 - 2031-12-24

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2016-06-01 - 2023-05-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated5Sites

2008-12-17 - 2009-12-20

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2017-03-01 - 2019-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2025-02-28 - 2032-06-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2017-09-01 - 2028-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated11Sites

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2014-11-06 - 2024-09-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2021-05-03 - 2034-02-28

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2015-07-31 - 2018-07-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated4Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2021-06-01 - 2031-12-24

Phase III

Active
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ATEZOLIZUMAB OR PLACEBO AND TRASTUZUMAB EMTANSINE FOR HER2-POSITIVE BREAST CANCER AT HIGH RISK OF RECURRENCE FOLLOWING PREOPERATIVE THERAPY 
  • Condition/Disease

    主要療效目的 本試驗的主要療效目的乃是根據下列指標,評估 atezolizumab 併用trastuzumab emtansine 相較於安慰劑加上 trastuzumab emtansine 的療效: IDFS,定義為自隨機分配

  • Test Drug

    注射液劑

Participate Sites
6Sites

Recruiting6Sites

1 2